Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. demonstrates a positive outlook due to the strengthening efficacy profile of its lead program, TARA-002, which has shown 100% durability and an 80% salvage rate upon re-induction, based on recent 6-month data. The company's intravenous choline chloride therapy has shown significant improvements in liver health compared to placebo in Phase 2 trials, highlighting its potential impact on intestinal failure associated liver disease (IFALD). With its robust safety profile and differentiated positioning in the non-muscle invasive bladder cancer (NMIBC) landscape, TARA-002 is well-positioned to compete effectively in the market, bolstering investor confidence in Protara's future growth prospects.

Bears say

Protara Therapeutics reported a net loss of $12.7 million, or $0.48 per share, in the fourth quarter of 2024, indicating ongoing financial challenges. Despite the promising early signals from its lead program, TARA-002, the stock remains significantly undervalued compared to peers, which raises concerns regarding market confidence and investor sentiment. Additionally, the competitive landscape in the NMIBC market may create hurdles, especially given the high bar set by other therapies and the critical supply issues affecting key treatment components like BCG.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.